VIPRD
Virtual Institute on Poverty Related Diseases

BIKTARVY

BIKTARVY® combines the DESCOVY® (FTC/TAF)* backbone with bictegravir, a novel, and unboosted INSTI—for a powerful STR with a high barrier to resistance1,2

No treatment-emergent resistance was associated with BIKTARVY in treatment-naïve clinical trials through Week 96 and in virologically suppressed clinical trials through Week 48†

Name: BIKTARVY